心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分

2021-05-07 澳大利亚国家心脏基金会 Med J Aust. 2021 May 7.

心血管疾病冠状动脉钙化

本文考虑了使用冠状动脉钙化评分（CAC）确定心血管风险的证据，本针对心血管疾病一级预防的冠状动脉钙化评分的应用提供指导建议。

中文标题：

2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分

英文标题：

National Heart Foundation of Australia: position statement on coronary artery calcium scoring for the primary prevention of cardiovascular disease in Australia

发布机构：

澳大利亚国家心脏基金会

发布日期：

2021-05-07

简要介绍：

本文考虑了使用冠状动脉钙化评分（CAC）确定心血管风险的证据，本针对心血管疾病一级预防的冠状动脉钙化评分的应用提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c353d1c002101115, title=2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分, enTitle=National Heart Foundation of Australia: position statement on coronary artery calcium scoring for the primary prevention of cardiovascular disease in Australia, guiderFrom=Med J Aust. 2021 May 7., authorId=0, author=, summary=本文考虑了使用冠状动脉钙化评分（CAC）确定心血管风险的证据，本针对心血管疾病一级预防的冠状动脉钙化评分的应用提供指导建议。, cover=https://img.medsci.cn/2021518/1621305064268_2020535.jpg, journalId=0, articlesId=null, associationId=412, associationName=澳大利亚国家心脏基金会, associationIntro=null, copyright=0, guiderPublishedTime=Fri May 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本文考虑了使用冠状动脉钙化评分（CAC）确定心血管风险的证据，本针对心血管疾病一级预防的冠状动脉钙化评分的应用提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=2529, tagName=心血管疾病), TagDto(tagId=5547, tagName=冠状动脉钙化)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2529, guiderKeyword=心血管疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11670, appHits=157, showAppHits=0, pcHits=785, showPcHits=11513, likes=1, shares=7, comments=10, approvalStatus=1, publishedTime=Tue May 18 10:40:22 CST 2021, publishedTimeString=2021-05-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue May 18 10:31:09 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 13:50:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分.pdf)])
2021 NHFA立场声明：心血管疾病一级预防的冠状动脉钙化评分.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1009777, encodeId=eb631009e77f3, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6b0b2d3a0add41aab0b7131586b1293c/d9a578def59f463dbe18f6b25cd983dc.jpg, createdBy=57862311617, createdName=ilzira, createdTime=Fri Aug 20 17:29:44 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005612, encodeId=ee7510056125f, content=想看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc495234187, createdName=147a8673m95暂无昵称, createdTime=Fri Aug 06 14:53:38 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002588, encodeId=3d81100258885, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:34 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002587, encodeId=091a100258e92, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:22 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970147, encodeId=23f59e014729, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/7bc23eec272e4164811f9db8c32bd6d0/224de44e1ed644e5b3a11a9ae2d4e078.jpg, createdBy=9d1c5453900, createdName=ms2000001864293950, createdTime=Tue Jun 01 19:58:34 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-08-20 ilzira

    想看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1009777, encodeId=eb631009e77f3, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6b0b2d3a0add41aab0b7131586b1293c/d9a578def59f463dbe18f6b25cd983dc.jpg, createdBy=57862311617, createdName=ilzira, createdTime=Fri Aug 20 17:29:44 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005612, encodeId=ee7510056125f, content=想看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc495234187, createdName=147a8673m95暂无昵称, createdTime=Fri Aug 06 14:53:38 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002588, encodeId=3d81100258885, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:34 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002587, encodeId=091a100258e92, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:22 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970147, encodeId=23f59e014729, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/7bc23eec272e4164811f9db8c32bd6d0/224de44e1ed644e5b3a11a9ae2d4e078.jpg, createdBy=9d1c5453900, createdName=ms2000001864293950, createdTime=Tue Jun 01 19:58:34 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-08-06 147a8673m95暂无昵称

    想看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1009777, encodeId=eb631009e77f3, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6b0b2d3a0add41aab0b7131586b1293c/d9a578def59f463dbe18f6b25cd983dc.jpg, createdBy=57862311617, createdName=ilzira, createdTime=Fri Aug 20 17:29:44 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005612, encodeId=ee7510056125f, content=想看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc495234187, createdName=147a8673m95暂无昵称, createdTime=Fri Aug 06 14:53:38 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002588, encodeId=3d81100258885, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:34 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002587, encodeId=091a100258e92, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:22 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970147, encodeId=23f59e014729, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/7bc23eec272e4164811f9db8c32bd6d0/224de44e1ed644e5b3a11a9ae2d4e078.jpg, createdBy=9d1c5453900, createdName=ms2000001864293950, createdTime=Tue Jun 01 19:58:34 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-07-25 ms7000000522684854

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1009777, encodeId=eb631009e77f3, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6b0b2d3a0add41aab0b7131586b1293c/d9a578def59f463dbe18f6b25cd983dc.jpg, createdBy=57862311617, createdName=ilzira, createdTime=Fri Aug 20 17:29:44 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005612, encodeId=ee7510056125f, content=想看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc495234187, createdName=147a8673m95暂无昵称, createdTime=Fri Aug 06 14:53:38 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002588, encodeId=3d81100258885, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:34 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002587, encodeId=091a100258e92, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:22 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970147, encodeId=23f59e014729, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/7bc23eec272e4164811f9db8c32bd6d0/224de44e1ed644e5b3a11a9ae2d4e078.jpg, createdBy=9d1c5453900, createdName=ms2000001864293950, createdTime=Tue Jun 01 19:58:34 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-07-25 ms7000000522684854

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1009777, encodeId=eb631009e77f3, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/6b0b2d3a0add41aab0b7131586b1293c/d9a578def59f463dbe18f6b25cd983dc.jpg, createdBy=57862311617, createdName=ilzira, createdTime=Fri Aug 20 17:29:44 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005612, encodeId=ee7510056125f, content=想看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc495234187, createdName=147a8673m95暂无昵称, createdTime=Fri Aug 06 14:53:38 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002588, encodeId=3d81100258885, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:34 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002587, encodeId=091a100258e92, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6035556648, createdName=ms7000000522684854, createdTime=Sun Jul 25 21:47:22 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970147, encodeId=23f59e014729, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210601/7bc23eec272e4164811f9db8c32bd6d0/224de44e1ed644e5b3a11a9ae2d4e078.jpg, createdBy=9d1c5453900, createdName=ms2000001864293950, createdTime=Tue Jun 01 19:58:34 CST 2021, time=2021-06-01, status=1, ipAttribution=)]
    2021-06-01 ms2000001864293950

    学习了

    0

相关指南

2021 CCS指南：成人心血管疾病预防中血脂异常的管理

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2021-03-26

2021 AHA科学声明：肥胖与心血管疾病

美国心脏协会(AHA,American Heart Association) · 2021-04-22

空气污染与心血管疾病专家共识

国家心血管病中心 · 2021-01-30

2020 BC指南：心血管疾病的一级预防（草案）

不列颠哥伦比亚省临床实践指南中心(BC,Clinical Practice Guidelines and Protocols in British Columbia) · 2020-06-20

2020 专家共识报告：牙周炎和心血管疾病

世界心脏病联盟(WHF,World Heart Federation) · 2020-02-20

《2019年欧洲心脏病学会和欧洲糖尿病研究学会糖尿病管理指南》解读

暂未更新 · 2019-10-30

拓展阅读

2014 AHA/ACC/HHS关于加强心血管疾病和共存疾病患者应用临床实践指南的策略

美国心脏协会(AHA,American Heart Association) · 2014-09-11

2014 BC临床指南：心血管疾病的一级预防

英国哥伦比亚临床实践指南中心(BC,Clinical Practice Guidelines and Protocols in British Columbia) · 2014-04-15

2015 AHA/ADA科学声明：成人2型糖尿病患者心血管疾病的预防（更新版）

美国糖尿病学会(ADA,American Diabetes Association) · 2015-08-05

2016 USPSTF建议声明：阿司匹林用于心血管疾病和结直肠癌的一级预防

美国预防医学工作组(USPSTF,U.S. Preventive Services Task Force) · 2016-04-12

2011 心血管疾病介入诊疗技术管理规范（2011年版）

暂未更新 · 2011-08-12

2016 AHA/ASA政策声明：姑息治疗与心血管疾病和中风

美国心脏协会(AHA,American Heart Association) · 2016-08-08